Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial

Abstract

Povidone-iodine (PVP-I) is a time-tested antiseptic agent with excellent virucidal (99.99%) properties. Repurposing it against coronavirus disease-19 (COVID-19) is a relatively newer concept and has been sparsely tested in vivo. The most common route of entry of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is the nasopharynx. Averting colonization of the virus could be one of the best options to reduce the incidence of infection. PVP-I gargle and mouthwash were found to be effective in vitro rapid inactivation against SARS-CoV-2 on a smaller scale (Hassandarvish et al. in BDJ 1–4, 2020, Pelletier et al. in ENTJ 1–5, 2020). However, efficacy in humans is lacking. To assess the virucidal effect of PVP-I against SARS-CoV-2 located in the nasopharynx was the objective of this parallel armed randomized clinical trial. We screened all RT-PCR-confirmed COVID-19 cases aged 18 years and above with symptoms. Written informed consent was obtained before randomization. Nasopharyngeal clearance of SARS-CoV-2 was tested after single time application of PVP-I nasal irrigation (NI) at diluted concentrations of .4%, .5% and .6% and PVP-I nasal spray (NS) at diluted concentrations of .5% and .6%. All groups were compared to the corresponding controls (distilled water). The primary outcome was viral clearance in a repeat RT-PCR (qualitative), and the secondary outcome was the number of adverse events. Final data analysis was performed using the statistical software SPSS (Version 20). A total of 189 confirmed COVID-19 cases were randomized into seven groups: 27 patients in each group. Of all, 159 (84.1%) were male, and 30 (15.9%) were female. We observed a statistically significant proportion of nasopharyngeal clearance with all strengths of PVP-I NI and PVP-I NS compared to the corresponding controlsAdditionally, 0.5% NI was significantly better than 0.5% NS for viral clearance (p = 0.018) and had the highest nasopharyngeal clearance among all strengths (n = 25, 92.6%). 0.6% NS is better than CNS and 0.5%NS in viral clearance. The only adverse event was nasal irritation recorded in two patients each in the 0.4% and 0.6% PVP-I NI groups (Tables 1 and 2). PVP-I NI and NS are proved as effective virucidal agent against SARS-CoV-2 in human body. Our recommendation is to use PVP-I in naopharynx (as well as oropharynx) to prevent COVID-19.

Introduction

Povidone-iodine (PVP-I) is a time-tested antiseptic agent with excellent virucidal (99.99%) properties. Repurposing it against coronavirus disease-19 (COVID-19) is a relatively newer concept and has been sparsely tested in vivo. The most common route of entry of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is the nasopharynx. Hence, it was targeted to prevent access and contamination of the nasopharynx by several protective measures, including facemasks. Averting colonization of the virus could be one of the best options to reduce the incidence of infection. PVP-I gargle and mouthwash were found to be effective in vitro rapid inactivation against SARS-CoV-2 on a smaller scale [1, 2]. However, efficacy in humans is lacking. To assess the virucidal effect of PVP-I against SARS-CoV-2 located in the nasopharynx was the objective of this parallel armed randomized clinical trial.

Methods

This single-center, open-label randomized clinical trial with a 7-arm parallel-group design was approved by the ethical review committee of Dhaka Medical College, Bangladesh. (NCT Identifier number: NCT04549376). We screened all reverse transcription-polymerase chain reaction (RT-PCR)-confirmed COVID-19 cases aged 18 years and above with symptoms. Written informed consent was obtained before randomization. Nasopharyngeal clearance of SARS-CoV-2 was tested after single time application of PVP-I nasal irrigation (NI) at diluted concentrations of 0.4%, 0.5% and 0.6% and PVP-I nasal spray (NS) at diluted concentrations of 0.5% and 0.6%. All groups were compared to the corresponding controls (distilled water). The primary outcome was viral clearance in a repeat RT-PCR (qualitative), and the secondary outcome was the number of adverse events. Final data analysis was performed using the statistical software SPSS (Version 20). The authors followed the Extension of the Consolidated Standards of Reporting Trials (CONSORT) 2010 guideline [3]. The study protocol was published elsewhere [4].

Results

A total of 189 confirmed COVID-19 cases were randomized into seven groups: 27 patients in each group. All of them completed the study. Of all, 159 (84.1%) were male, and 30 (15.9%) were female. The average age of the participants was 43.98 ± 12.67 years (SD), with the majority ranging from 31 to 40 years (n = 56, 29.60%). The PVP-I NS group had significantly higher proportions of severe patients than the control-NS (C-NS) group (p < 0.001). The 0.6% NS group differed from the C-NS group by sex and the presence of comorbidities (p < 0.05). Adjusting the differences, we observed a statistically significant proportion of nasopharyngeal clearance with all strengths of PVP-I NI and PVP-I NS compared to the corresponding controls. Additionally, 0.5% NI was significantly better than 0.5% NS for viral clearance (p = 0.018) and had the highest nasopharyngeal clearance among all strengths (n = 25, 92.6%) and 0.6% NS is best among 0.5% NS and CNS. The only adverse event was nasal irritation recorded in two patients each in the 0.4% and 0.6% PVP-I NI groups (Tables 1 and 2).

Table 1 Patient Demographics, baseline clinical characteristics and virucidal activity of PVI-P Nasal spray and mouth wash
Table 2 Level of significance table for pair-wise comparisons of patient demographics, baseline clinical characteristics and virucidal activity of PVI-P Nasal spray and mouth wash

Discussion

Although in vitro testing of PVP-I solution revealed a considerable reduction in SARS-CoV-2 viral titers, its effect on humans was unclear [1]. Our study confirms the presumed effectiveness of PVP-I in nasopharyngeal clearance of SARS-CoV-2 among COVID-19 patients. Compared to controls, we noted viral clearance at two-fifth to three-fifth dilutions of PVP-I nasal irrigation and spray. Our findings agree with the first report of in vivo PVP-I mouthwash application [5]. In contrast, Guenezan et al. [6] observed no effect of PVP-I on nasopharyngeal viral loads. They reported unpleasant nasal tingling and transient elevation of thyroid stimulating hormone after povidone iodine administration. In contrast, we found nasal irritation in only two patients (1.1%). Our study’s strength was testing different strengths of PVP-I nasal solution and comparing those with distilled water controls in a modest number of cases. However, our limitation was the inability to conduct viral quantification before and after intervention.

Conclusion

In this study, a statistically significant proportion of nasopharyngeal clearance with all strengths of PVP-I NI and PVP-I NS (compared to the corresponding controls) is observed, so our recommendation is to use PVP-I prophylactically in nasopharynx as well as oropharynx (through which areas SARS-CoV-2 enters and resides for a while) for prevention of COVID-19.

Data Availability

The corresponding author has access to the all-trial information, and the data will be available on reasonable request (contact: dr.jahid61@gmail.com or arefin61dmc@gmail.com).

References

  1. 1.

    Hassandarvish P, Tiong V, Mohamed NA et al (2020) In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice. Br Dent J. https://doi.org/10.1038/s41415-020-2402-0

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Pelletier JS, Tessema B, Frank S, Westover JB, Brown SM, Capriotti JA (2020) Efficacy of povidone-iodine nasal and oral antiseptic preparations against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Ear Nose Throat J. https://doi.org/10.1177/0145561320957237

    Article  PubMed  Google Scholar 

  3. 3.

    Juszczak E, Altman DG, Hopewell S, Schulz K (2019) Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement. JAMA 321(16):1610–1620. https://doi.org/10.1001/jama.2019.3087

    Article  PubMed  Google Scholar 

  4. 4.

    Hasan MJ, Rumi SKNF, Banu SS, Uddin AKMN, Islam MS, Arefin MK (2021) Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: a structured summary of a study protocol for an open-label randomized clinical trial. Trials 22:2. https://doi.org/10.1186/s13063-020-04963-2

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Lamas LM, Dios PD, Rodríguez MTP et al (2020) Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo Tests Oral Dis. https://doi.org/10.1111/odi.13526

    Article  Google Scholar 

  6. 6.

    Guenezan J, Garcia M, Strasters D et al (2021) Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19. JAMA-Otolaryngol Neck Surg 9(6):1871. https://doi.org/10.1001/jamaoto.2020.5490

    Article  Google Scholar 

Download references

Acknowledgements

The authors acknowledge significant support from the Pi Research Consultancy Center, Dhaka, Bangladesh (www.pircc.org) in overall research activities. Also, thanks to the BRICM for material support. The authors would like to thank all the clinical staff of the DMCH for their cordial assistance.

Funding

The trial received research partial grant from BRICM.

Author information

Affiliations

Authors

Contributions

MKA had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Conception of the research idea: MKA. Research design: MKA and MJH. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript: All authors. Statistical analysis: ASK, MKA and MJH. Administrative, technical, or material support: AKMNU, MK and SSB. Supervision: MKA, SKNFR, and MJH. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Mostafa Kamal Arefin.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval

The RCT protocol was approved by the Ethical Review Committee of Dhaka Medical College (Memo No: ERC-DMC/ECC/2020/93) on 23 May 2020.

Trial registration

The trial protocol has been registered at ClinicalTrials.gov on September 16, 2020. NCT Identifier Number: NCT04549376. (https://clinicaltrials.gov/ct2/show/NCT04549376).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Arefin, M.K., Rumi, S.N.F., Uddin, A.N. et al. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial. Indian J Otolaryngol Head Neck Surg (2021). https://doi.org/10.1007/s12070-021-02616-7

Download citation

Keywords

  • COVID-19
  • Povidone Iodine
  • Nasal spray
  • Nasal Irrigation